Peter Mullen School of Medicine University of St Andrews Biography Publications Institution JoVE Articles Peter Mullen has not added a biography. If you are Peter Mullen and would like to personalize this page please email our Author Liaison for assistance. Publications New Strategies for Targeting the Hypoxic Tumour Microenvironment in Breast Cancer Cancer Treatment Reviews. Apr, 2013 | Pubmed ID: 23063837 Effect of Short- and Long-term Treatment with Valproate on Carnitine Homeostasis in Humans Therapeutic Drug Monitoring. Aug, 2012 | Pubmed ID: 22743351 Ureido-substituted Sulfamates Show Potent Carbonic Anhydrase IX Inhibitory and Antiproliferative Activities Against Breast Cancer Cell Lines Bioorganic & Medicinal Chemistry Letters. Jul, 2012 | Pubmed ID: 22721713 Diversity of Matriptase Expression Level and Function in Breast Cancer PloS One. 2012 | Pubmed ID: 22514623 Features of the Reversible Sensitivity-resistance Transition in PI3K/PTEN/AKT Signalling Network After HER2 Inhibition Cellular Signalling. Feb, 2012 | Pubmed ID: 21996585 Model-based Global Sensitivity Analysis As Applied to Identification of Anti-cancer Drug Targets and Biomarkers of Drug Resistance in the ErbB2/3 Network European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences. Nov, 2011 | Pubmed ID: 22085636 Sprouty 2 is an Independent Prognostic Factor in Breast Cancer and May Be Useful in Stratifying Patients for Trastuzumab Therapy PloS One. 2011 | Pubmed ID: 21909357 Susceptibility to Simvastatin-induced Toxicity is Partly Determined by Mitochondrial Respiration and Phosphorylation State of Akt Biochimica Et Biophysica Acta. Dec, 2011 | Pubmed ID: 21839782 Trastuzumab and Pertuzumab Produce Changes in Morphology and Estrogen Receptor Signaling in Ovarian Cancer Xenografts Revealing New Treatment Strategies Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Jul, 2011 | Pubmed ID: 21571868 Phosphoprotein Pathway Profiling of Ovarian Carcinoma for the Identification of Potential New Targets for Therapy European Journal of Cancer (Oxford, England : 1990). Jun, 2011 | Pubmed ID: 21334202 Tyrosine Phosphorylation Profiling Reveals the Signaling Network Characteristics of Basal Breast Cancer Cells Cancer Research. Nov, 2010 | Pubmed ID: 20861192 Pertuzumab for the Treatment of Ovarian Cancer Expert Opinion on Biological Therapy. Jul, 2010 | Pubmed ID: 20465533 Serotonin, a Catecholamine? Headache. Apr, 2010 | Pubmed ID: 20100295 Effect of Simvastatin on Cholesterol Metabolism in C2C12 Myotubes and HepG2 Cells, and Consequences for Statin-induced Myopathy Biochemical Pharmacology. Apr, 2010 | Pubmed ID: 20018177 Modulation of HER3 is a Marker of Dynamic Cell Signaling in Ovarian Cancer: Implications for Pertuzumab Sensitivity Molecular Cancer Research : MCR. Sep, 2009 | Pubmed ID: 19737968 Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab Cancer Research. Aug, 2009 | Pubmed ID: 19638581 Gonadotropin-releasing Hormone Receptor Levels and Cell Context Affect Tumor Cell Responses to Agonist in Vitro and in Vivo Cancer Research. Aug, 2008 | Pubmed ID: 18676858 Sensitivity to Pertuzumab (2C4) in Ovarian Cancer Models: Cross-talk with Estrogen Receptor Signaling Molecular Cancer Therapeutics. Jan, 2007 | Pubmed ID: 17237269 Raf-1 is the Predominant Raf Isoform That Mediates Growth Factor-stimulated Growth in Ovarian Cancer Cells Carcinogenesis. Apr, 2006 | Pubmed ID: 16332724 Comparison of Strategies Targeting Raf-1 MRNA in Ovarian Cancer International Journal of Cancer. Journal International Du Cancer. Mar, 2006 | Pubmed ID: 16184551 Altered ErbB Receptor Signaling and Gene Expression in Cisplatin-resistant Ovarian Cancer Cancer Research. Aug, 2005 | Pubmed ID: 16061661 Antisense Oligonucleotide Targeting of Raf-1: Importance of Raf-1 MRNA Expression Levels and Raf-1-dependent Signaling in Determining Growth Response in Ovarian Cancer Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Mar, 2004 | Pubmed ID: 15041731 The Use of Matrigel to Facilitate the Establishment of Human Cancer Cell Lines As Xenografts Methods in Molecular Medicine. 2004 | Pubmed ID: 14634240 Flow Cytometric DNA Analysis of Human Cancer Cell Lines Methods in Molecular Medicine. 2004 | Pubmed ID: 14634236 PARP Cleavage As a Means of Assessing Apoptosis Methods in Molecular Medicine. 2004 | Pubmed ID: 14634228 השימוש במערכי חלבון שלב הפוכים (RPPA) לחקור וריאצית ביטוי חלבון בתוך הסרטן של תאי כליה בודד Fiach C. O'Mahony1, Jyoti Nanda1, Alexander Laird1, Peter Mullen2, Helen Caldwell3, Ian M. Overton4, Lel Eory4, Marie O'Donnell1,5, Dana Faratian6, Thomas Powles7, David J. Harrison1,2, Grant D. Stewart1 1Edinburgh Urological Cancer Group, University of Edinburgh, 2School of Medicine, University of St Andrews, 3Division of Pathology, University of Edinburgh, 4MRC Human Genetics Unit, MRC IGMM, University of Edinburgh, 5Department of Pathology, Western General Hospital, 6Breakthrough Breast Cancer Research Unit, University of Edinburgh, 7St Bartholomew's Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London JoVE 50221 Medicine
השימוש במערכי חלבון שלב הפוכים (RPPA) לחקור וריאצית ביטוי חלבון בתוך הסרטן של תאי כליה בודד Fiach C. O'Mahony1, Jyoti Nanda1, Alexander Laird1, Peter Mullen2, Helen Caldwell3, Ian M. Overton4, Lel Eory4, Marie O'Donnell1,5, Dana Faratian6, Thomas Powles7, David J. Harrison1,2, Grant D. Stewart1 1Edinburgh Urological Cancer Group, University of Edinburgh, 2School of Medicine, University of St Andrews, 3Division of Pathology, University of Edinburgh, 4MRC Human Genetics Unit, MRC IGMM, University of Edinburgh, 5Department of Pathology, Western General Hospital, 6Breakthrough Breast Cancer Research Unit, University of Edinburgh, 7St Bartholomew's Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London JoVE 50221 Medicine